Related Experiment Video
Updated: Dec 28, 2025
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Prospects for Therapies in Osteoarthritis
Asim Ghouri1, Philip G Conaghan2,3
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.
Abstract:
Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.
Insights
Osteoarthritis (OA) management needs better drugs. Disease-modifying osteoarthritis drugs (DMOADs) show promise for structural repair and symptom relief, but future trials require careful consideration.
Area of Science:
- Rheumatology
- Pharmacology
- Biomedical Engineering
Background:
- Osteoarthritis (OA) is a widespread, chronic disease impacting millions globally.
- Current OA treatments, including conventional drugs, offer limited efficacy and side effects.
- Novel pharmacological therapies targeting bone, cartilage, synovium, and nerves are needed.
Purpose of the Study:
- To review the current landscape of osteoarthritis pharmacotherapy.
- To evaluate the progress and challenges in developing disease-modifying osteoarthritis drugs (DMOADs).
- To identify key considerations for future clinical trials of OA therapies.
Main Methods:
- Literature review of recent studies on OA pharmacological treatments.
- Analysis of therapeutic targets in OA, including bone, cartilage, synovium, and nerves.
- Evaluation of outcomes from recent DMOAD trials.
Main Results:
- Despite efforts, developing effective OA therapies has faced significant challenges.
- Some DMOAD candidates have shown preliminary promise in targeting structural pathologies.
- Limited success highlights the complexity of OA and the need for refined therapeutic strategies.
Conclusions:
- There is an unmet need for effective pharmacological treatments for osteoarthritis.
- Disease-modifying osteoarthritis drugs (DMOADs) represent a promising avenue, though challenges remain.
- Future research and clinical trials must incorporate lessons learned to advance OA management.
